SCHEMBL17257482

SCHEMBL17257482

C/C(=N\OS(=O)(=O)c1ccccc1)c1c(C#N)ccn1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.39
MAPT P10636 7/20 0.37
ALDH1A1 P00352 10/20 0.36
KDM4E B2RXH2 6/20 0.36
KMT2A Q03164 3/20 0.36
IMPDH2 P12268 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
SCN9A Q15858 1/20 0.34
XBP1 P17861 4/20 0.33
MPI P34949 4/20 0.33
NPSR1 Q6W5P4 4/20 0.33
HSP90AA1 P07900 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
S1PR2 O95136 3/20 0.32
LMNA P02545 3/20 0.32
HTT P42858 3/20 0.32
RAB9A P51151 2/20 0.32
PKM P14618 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17257483 1.00 MAPK1 (0.39) MAPK1MAPTALDH1A1KDM4EKMT2A
SCHEMBL17257393 0.81 MAPT (0.37) MAPK1MAPTALDH1A1KDM4EKMT2A
SCHEMBL17257278 0.78 MAPT (0.41) MAPK1MAPTALDH1A1KDM4EKMT2A
SCHEMBL17257276 0.78 MAPT (0.41) MAPK1MAPTALDH1A1KDM4EKMT2A
SCHEMBL17256771 0.76 LMNA (0.34) MAPTIMPDH2LMNA
SCHEMBL17256773 0.76 LMNA (0.34) MAPTIMPDH2LMNA
SCHEMBL17257397 0.75 ALDH1A1 (0.34) MAPK1MAPTALDH1A1KDM4EIMPDH2
SCHEMBL17257663 0.75 CTDSP1 (0.39) MAPK1MAPTALDH1A1KDM4EKMT2A
SCHEMBL17256883 0.75 ALDH1A1 (0.34) MAPK1MAPTALDH1A1KDM4EIMPDH2
SCHEMBL17257664 0.75 CTDSP1 (0.39) MAPK1MAPTALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US claimed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US claimed
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US disclosed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group PAM, PPOX, MB MAPK1 1603/4885MAPT 2157/4885ALDH1A1 3041/4885
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP PAM, PPOX, MB MAPK1 1603/4885MAPT 2157/4885ALDH1A1 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.